Short answer
Phreesia, Inc. (PHR) filed an 8-K current report with the SEC on April 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Standard forward-looking statement disclaimer accompanying Phreesia’s fiscal 2026 disclosure.
Phreesia, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Standard forward-looking statement disclaimer accompanying Phreesia’s fiscal 2026 disclosure
- Future projections subject to material risks and uncertainties described in the January 31, 2026 Form 10-K
- Investors should rely on reported results and guidance details in the accompanying exhibit, not disclaimer language
Item EX-99.1 · Exhibit EX-99.1
- Q4 FY2026 revenue $127.1M, up 16% YoY; AccessOne excluded, growth was 7%
- Adjusted EBITDA $29.4M, up from $16.4M; margin reached 23%
- FY2026 crossed $100M adjusted EBITDA, $50M free cash flow, and first positive full-year GAAP net income
- FY2027 revenue outlook cut to $510M-$520M from $545M-$559M amid weaker pharmaceutical commitments
- FY2027 adjusted EBITDA maintained at $125M-$135M, highlighting operating leverage and planned AI-driven efficiencies
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Phreesia, Inc. 8-K filings
Get the next PHR 8-K as it lands
Follow PHR for push alerts, or ask the research agent what this filing means.